Peter Gøtzsche, MD
September 9, 2013
There are many good books about the crimes in the drug industry and the widespread corruption of the profession to which I belong; doctors. I had therefore promised myself that I would not write one. But two things in particular made me change my mind in the summer of 2012.
In 2007, PhD student Anders Jørgensen and I applied for access to trial protocols and clinical study reports for two slimming pills at the European Medicines Agency (EMA). Our request was flatly denied with the excuse that the documents could not be released because it would undermine commercial interests. We complained to the European ombudsman, and he agreed with us that these documents did not contain commercially confidential information. When, after 3 years, the agency was still completely resistant to our arguments and those of the ombudsman, he accused the EMA of maladministration. This caused the EMA to change its stance completely. Its director left the agency to consult for drug companies, and the new director introduced a far-reaching openness policy in accordance with the ombudsman’s wishes and in accordance with the principles on which the EU are based.>Complete report<